Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noriyuki Okonogi

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
International Journal of Clinical Oncology|April 5, 2020
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatmentHiro Sato, Noriyuki Okonogi, Takashi Nakano
Lancet (London, England)|November 23, 2024
Pembrolizumab for locally advanced cervical cancerNaoya Murakami, Noriyuki Okonogi, Yasuhisa Terao, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 14, 2019
[Radiotherapy and PD-L1 Expression]Hiro Sato, Noriyuki Okonogi, Yuya Yoshimoto, et al.
International Journal of Particle Therapy|April 16, 2025
Dose Constraints in Carbon-Ion Radiation Therapy to Minimize the Risk of Pectoral MyositisNoriyuki Okonogi, Kumiko Karasawa, Kazutoshi Murata, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2026
Carbon-Ion Radiation Therapy as Nonsurgical Treatment for Early-Stage Breast Cancer: 5-Year Results From the Phase 2 Part of the First Prospective Clinical TrialNoriyuki Okonogi, Kukimo Karasawa, Kazutoshi Murata, et al.
Breast Cancer Research and Treatment|July 5, 2022
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancerNoriyuki Okonogi, Kumiko Karasawa, Yuki Nitta, et al.
Cancers|November 13, 2021
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?Amelia Barcellini, Pierre Loap, Kazutoshi Murata, et al.
Anticancer Research|March 10, 2015
Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiformeNoriyuki Okonogi, Katsuyuki Shirai, Takahiro Oike, et al.
Cancer Reports (Hoboken, N.J.)|March 1, 2022
Clinical advantage and outcomes of computed tomography-based transvaginal hybrid brachytherapy performed only by sedation without general or saddle block anesthesiaNoriyuki Okonogi, Kazutoshi Murata, Toshiaki Matsui, et al.
Journal of Radiation Research|June 28, 2018
High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cellsMasahiro Onishi, Noriyuki Okonogi, Takahiro Oike, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
International Journal of Clinical Oncology|April 5, 2020
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatmentHiro Sato, Noriyuki Okonogi, Takashi Nakano
Lancet (London, England)|November 23, 2024
Pembrolizumab for locally advanced cervical cancerNaoya Murakami, Noriyuki Okonogi, Yasuhisa Terao, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 14, 2019
[Radiotherapy and PD-L1 Expression]Hiro Sato, Noriyuki Okonogi, Yuya Yoshimoto, et al.
International Journal of Particle Therapy|April 16, 2025
Dose Constraints in Carbon-Ion Radiation Therapy to Minimize the Risk of Pectoral MyositisNoriyuki Okonogi, Kumiko Karasawa, Kazutoshi Murata, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2026
Carbon-Ion Radiation Therapy as Nonsurgical Treatment for Early-Stage Breast Cancer: 5-Year Results From the Phase 2 Part of the First Prospective Clinical TrialNoriyuki Okonogi, Kukimo Karasawa, Kazutoshi Murata, et al.
Breast Cancer Research and Treatment|July 5, 2022
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancerNoriyuki Okonogi, Kumiko Karasawa, Yuki Nitta, et al.
Cancers|November 13, 2021
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?Amelia Barcellini, Pierre Loap, Kazutoshi Murata, et al.
Anticancer Research|March 10, 2015
Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiformeNoriyuki Okonogi, Katsuyuki Shirai, Takahiro Oike, et al.
Cancer Reports (Hoboken, N.J.)|March 1, 2022
Clinical advantage and outcomes of computed tomography-based transvaginal hybrid brachytherapy performed only by sedation without general or saddle block anesthesiaNoriyuki Okonogi, Kazutoshi Murata, Toshiaki Matsui, et al.
Journal of Radiation Research|June 28, 2018
High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cellsMasahiro Onishi, Noriyuki Okonogi, Takahiro Oike, et al.
Pageof 10